Unum Therapeutics to Review Second Quarter 2019 Financial Results on August 12, 2019
August 02 2019 - 9:00AM
Unum Therapeutics Inc. (Nasdaq: UMRX), a biopharmaceutical company
focused on developing potentially curative cellular immunotherapies
through its ACTR and BOXR platforms, today announced that the
company will host a conference call and live audio webcast on
Monday, August 12, 2019 at 4:30 p.m. ET to discuss financial
results for the second quarter of 2019. Unum management will also
provide an update on the Company’s recent progress and upcoming
milestones.
Participants may access the conference call by dialing
866-300-3411 (domestic) or 636-812-6658 (international) and refer
to conference ID number 5658375. To join the live webcast, please
visit the investor relations section of the Unum Therapeutics
website at https://investors.unumrx.com/ at least 10 minutes before
the event begins.
A webcast replay will be available at the same location on the
Unum Therapeutics website beginning approximately two hours after
the event and will be archived for 90 days.
About Unum Therapeutics
Unum Therapeutics is a clinical-stage
biopharmaceutical company focused on developing potentially
curative T cell therapies to treat a broad range of cancer
patients. Unum’s novel proprietary technologies include
Antibody-Coupled T cell Receptor (ACTR), an autologous engineered
T-cell therapy that combines the cell-killing ability of T cells
and the tumor-targeting ability of co-administered antibodies to
exert potent antitumor immune responses, and Bolt-On Chimeric
Receptor (BOXR), designed to improve engineered T cells by
incorporating a “bolt-on” transgene to overcome the solid tumor
microenvironment. Unum has multiple programs in Phase 1 clinical
testing, including ACTR707 used in combination with rituximab in
adult patients with r/r NHL and used in combination with
trastuzumab in adult patients with HER2+ advanced cancer, and
ACTR087 used in combination with the novel antibody SEA-BCMA in r/r
multiple myeloma. The Company is headquartered in Cambridge,
MA.
Investor Contact:Stephanie Ascher,
212-362-1200stephanie@sternir.com
Media Contact:Lissette Steele,
202-930-4762lsteele@vergescientific.com
Unum Therapeutics (NASDAQ:UMRX)
Historical Stock Chart
From Apr 2024 to May 2024
Unum Therapeutics (NASDAQ:UMRX)
Historical Stock Chart
From May 2023 to May 2024